Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves Perrigo's miconazole

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Perrigo's abbreviated new drug application for the private-label version of Monistat-1 Combination Pack. Perrigo's OTC Miconazole Nitrate Vaginal Cream and Suppository will ship immediately, the Allegan, Mich.-based private label firm says June 3. Johnson & Johnson/McNeil's Monistat generates about $90 million in annual sales, Perrigo pointed out. Perrigo also said patent litigation by J&J was dismissed, and the approval includes 180 days of generic marketing exclusivity. Analysts with Collins Stewart say the launch of Perrigo's store-brand Monistat product is positive and "gives us greater confidence in [Perrigo's] manufacturing capabilities.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS104177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel